Özge Altuğ Gücenmez

Özge Altuğ Gücenmez

Auto-generated profile, based on publicly available information

Özge Altuğ Gücenmez

University of Health Sciences, Izmir Behçet Uz Children Hospital, Department of Pediatric Rheumatology Izmir Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
BSBetul Sozeri
Betul Sozeri
KUKadir Ulu
Kadir Ulu
UKUmmusen Kaya-Akça
Ummusen Kaya-Akça
FHFatih Haslak
Fatih Haslak
AKAyşenur Paç Kısaarslan
Ayşenur Paç Kısaarslan
NANuray Aktay Ayaz
Nuray Aktay Ayaz

21 October 2018 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
OGOzge Altug Gucenmez
Ozge Altug Gucenmez
TKTuncay Kume
Tuncay Kume
BMBalahan Makay
Balahan Makay
OBOmur Babayigit
Omur Babayigit
NANur Arslan
Nur Arslan
EUErbil Unsal
Erbil Unsal

21 April 2025 in Rheumatology
Verified
Journal Article
Closed access
ETEray Tunce
Eray Tunce
SUSıla Atamyıldız Uçar
Sıla Atamyıldız Uçar
MPMerve Cansu Polat
Merve Cansu Polat
ÖGÖzge Altuğ Gücenmez
Özge Altuğ Gücenmez
MÇMustafa Çakan
Mustafa Çakan
BSBetul Sozeri
Betul Sozeri
Objectives: This study aimed to evaluate the predictability of the homozygous M694V genotype in paediatric FMF patients and to develop a clinical scoring system to enhance disease management strategies. Methods: This nationwide, multicentre, cross-sectional study included 3981 paediatric FMF patients with biallelic pathogenic variants in exon 10 of the Mediterranean fever gene. Patients were divided into two groups: group 1 (homozygous M694V) and group 2 (other variants). Data were collected from 37 paediatric rheumatology and/or nephrology clinics across Türkiye, covering patients followed between 2014 and 2023. Results: Group 1 had significantly earlier symptom onset (≤3 years: 49.8% vs 43.9%, P < 0.001) and diagnosis (median age: 5 years vs 5.8 years, P < 0.001) compared with group 2. A higher prevalence of family history of FMF was observed in group 1 (P < 0.001). Clinical manifestations, including arthritis (27.5%), erysipelas-like erythema (ELE) (20.3%) and protracted febrile myalgia syndrome (PFMS) (3.6%), were significantly more frequent in group 1 (P < 0.001 for all). Colchicine resistance was also higher in group 1 (18.1% vs 5.1%, P < 0.001). Logistic regression analysis showed that ≤3 years of age at symptom onset, family history, arthritis, myalgia, PFMS, ELE and splenomegaly were independent predictors of the homozygous M694V genotype. A clinical scoring system was proposed based on these findings. Conclusion: This study provides valuable insights into the clinical predictors of the homozygous M694V genotype in paediatric FMF. The proposed scoring system will support clinicians in prognosis assessment and treatment planning, contributing to improved patient outcomes.

14 November 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
DBDeniz Bayraktar
Deniz Bayraktar
SSSema Savci
Sema Savci
OAOzge Altug-Gucenmez
Ozge Altug-Gucenmez
Egemen MANCIEgemen MANCI
Egemen MANCI
BMBalahan Makay
Balahan Makay
EUErbil Unsal
Erbil Unsal

1 December 2023 in Pediatric Pulmonology
Verified
Journal Article
Open access
DSDevrim Can Sarac
Devrim Can Sarac
DBDeniz Bayraktar
Deniz Bayraktar
DKDerya Ozer Kaya
Derya Ozer Kaya
OGOzge Altug Gucenmez
Ozge Altug Gucenmez
DODeran Oskay
Deran Oskay
Introduction: Although inspiratory muscle training (IMT) has proven effective in adult rheumatic diseases, its impact on juvenile idiopathic arthritis (JIA) remains unexplored. The present study aimed to investigate the effects of IMT in children with JIA.Methods: Thirty‐three children (13–18 years) with JIA were divided into two groups as exercise (n = 17) and control (n = 16). The exercise group performed IMT at home daily for 8 weeks. The initial IMT load was set as 60% of maximal inspiratory pressure (PImax) and increased by %10 of the initial load every 2 weeks. The control group received no additional intervention. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FVC/FEV1, PImax, and maximal expiratory pressure (PEmax) were evaluated. Peak oxygen consumption (VO2max), metabolic equivalents (METs), and maximal heart rate were measured with cardiopulmonary exercise test. Functional capacity and quality of life were assessed with 6‐min walk distance and Pediatric Quality of Life Inventory 3.0 Arthritis Module. All participants were evaluated at baseline and post‐treatment.Results: FVC ( ↑ 0.20 (95% CI: 0.07/0.32) liters), FEV1 ( ↑ 0.14 (95% CI: 0.02/0.25) liters), PImax (↑19.11 (95% CI: 9.52/28.71) cmH2O), PEmax (↑12.41 (95% CI: 3.09/21.72) cmH2O), VO2peak (↑158.29 (95% CI: 63.85/252.73) ml/min), and METs (↑0.92 (95% CI: 0.34/1.49) [ml/kg/min]) significantly improved only in the exercise group (p < .05). The difference over time in FVC, FEV1, PImax, VO2peak, and METs were significantly higher in exercise group compared to control group (p < .05).Conclusions: IMT seems to be an effective option for improving respiratory functions and aerobic exercise capacity in JIA.

16 September 2025 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
COCagla Ozbakir
Cagla Ozbakir
OGOzge Altug Gucenmez
Ozge Altug Gucenmez